心房颤动作为依洛尤单抗可能的不良反应。
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab.
作者信息
Abdelmaseih Ramy, Abdelmasih Randa, Hasan Mustajab, Hamza Alan
机构信息
Internal Medicine, University of Central Florida College of Medicine, Ocala, USA.
出版信息
Cureus. 2021 Jun 5;13(6):e15467. doi: 10.7759/cureus.15467. eCollection 2021 Jun.
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.
依洛尤单抗是一种最近获得美国食品药品监督管理局（FDA）批准的前蛋白转化酶枯草溶菌素/kexin 9型抑制剂（PCSK9i），可降低已确诊的动脉粥样硬化性心血管疾病患者发生心肌梗死、中风和冠状动脉血运重建的风险。我们报告了依洛尤单抗出现的一种极其罕见的可能副作用——心房颤动（AF），以提高医生对这种可能性的认识。
Zotero 插件